At the time of writing, Bioventus Inc [BVS] stock is trading at $7.65, down -0.65%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BVS shares have gain 3.66% over the last week, with a monthly amount glided 14.52%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bioventus Inc [NASDAQ: BVS] stock has seen the most recent analyst activity on July 07, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $12. Previously, JP Morgan upgraded its rating to Neutral on December 17, 2024, and elevated its price target to $13. On December 07, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $7 on the stock. Craig Hallum upgraded its rating to a Buy and increased its price target to $6 on August 09, 2023. Craig Hallum downgraded its rating to a Hold. JP Morgan downgraded its rating to Underweight for this stock on November 09, 2022. In a note dated November 09, 2022, Canaccord Genuity downgraded an Hold rating on this stock and revised its target price from $18 to $6.
For the past year, the stock price of Bioventus Inc fluctuated between $5.81 and $12.61. Currently, Wall Street analysts expect the stock to reach $9.83 within the next 12 months. Bioventus Inc [NASDAQ: BVS] shares were valued at $7.65 at the most recent close of the market. An investor can expect a potential return of 28.5% based on the average BVS price forecast.
Analyzing the BVS fundamentals
According to Bioventus Inc [NASDAQ:BVS], the company’s sales were 563.83M for trailing twelve months, which represents an -0.23% plunge. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is 0.01%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.05 and Total Capital is 0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.45 points at the first support level, and at 7.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.82, and for the 2nd resistance point, it is at 7.98.
Ratios To Look Out For
It is important to note that Bioventus Inc [NASDAQ:BVS] has a current ratio of 1.74. Further, the Quick Ratio stands at 1.14, while the Cash Ratio is 0.26. Considering the valuation of this stock, the price to sales ratio is 1.12, the price to book ratio is 3.08 and price to earnings (TTM) ratio is 68.12.
Transactions by insiders
Recent insider trading involved McMurry-Heath Michelle, Director, that happened on Nov 07 ’25 when 17701.0 shares were sold. Director, McMurry-Heath Michelle completed a deal on Nov 07 ’25 to buy 27000.0 shares. Meanwhile, SVP & CFO Singleton Mark Leonard sold 3875.0 shares on Apr 11 ’25.
